

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
MicroRNA and small interfering RNA combination therapy for cancer	<p>Mouse and cell culture studies suggest combined use of miRNA and siRNA against a target could be useful for treating cancer. In human ovarian cancer cell lines, miR-520d-3p was shown to be tumor suppressive and decrease EPH receptor A2 (EPHA2) and EPHB2 expression compared with no treatment. In two mouse xenograft models of ovarian cancer, liposomes loaded with miR-520d-3p and siRNA against EPHA2 inhibited growth more potently than liposomes loaded with one of the two RNAs. Next steps could include testing the siRNA and miRNA combination in other tumor models with elevated EPHA2 expression.</p> <p><i>SciBX</i> 6(39); doi:10.1038/scibx.2013.1112 Published online Oct. 10, 2013</p>	Patent and licensing status unavailable	<p>Nishimura, M. <i>et al. Cancer Discov.</i>; published online Sept. 3, 2013; doi:10.1158/2159-8290.CD-13-0159 Contact: George A. Calin, The University of Texas MD Anderson Cancer Center, Houston, Texas e-mail: gcalin@mdanderson.org</p>